5 Key Takeaways

• 1

  The FDA plans to streamline biosimilar drug regulation, potentially halving the time and cost for market entry.

• 2

  Biosimilars can cost up to 90% less than brand-name biologics, which account for over half of U.S. drug spending.

• 3

  The U.S. Patent Office's new rules are making it harder for biosimilar makers to challenge brand-name patents.

• 4

  Biosimilar competition is crucial for reducing prescription drug prices, despite regulatory and patent challenges.

• 5

  The FDA's new rules may lower development costs but won't necessarily expedite market entry for biosimilars.